DCM
INSY

Dialectic Capital Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Dialectic Capital Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-25,000
Closed -$295K – 120
2016
Q3 		$295K Buy
+25,000
New +$380K 0.18% 81

Other funds holding INSY

SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dialectic Capital Management's INSY Position: Q2 2016 in Review

Dialectic Capital Management sold out of Insys Therapeutics, Inc. (INSY) in Q2 2016, closing a stake of 79,550 shares — an estimated $1.27M sold.

Dialectic Capital Management first reported a position in INSY in Q1 2016 and held it in 1 quarter. The position peaked at $1.27M in Q1 2016. 124 funds tracked by Wall St. Rank hold INSY as of Q2 2016.

  • Dialectic Capital Management reported no remaining Insys Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • Dialectic Capital Management sold 79,550 Insys Therapeutics, Inc. shares in Q2 2016, an estimated $1.27M.
  • Dialectic Capital Management first reported a position in Insys Therapeutics, Inc. in Q1 2016 and held it in 1 quarter.
  • Dialectic Capital Management's Insys Therapeutics, Inc. position peaked at $1.27M in Q1 2016.
  • 124 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2016.

Based on Dialectic Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.